| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARL11 |
| Uniprot No | Q969Q4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-196aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSVNSRGHK AEAQVVMMGL DSAGKTTLLY KLKGHQLVET LPTVGFNVEP LKAPGHVSLT LWDVGGQAPL RASWKDYLEG TDILVYVLDS TDEARLPESA AELTEVLNDP NMAGVPFLVL ANKQEAPDAL PLLKIRNRLS LERFQDHCWE LRGCSALTGE GLPEALQSLW SLLKSRSCMC LQARAHGAER GDSKRS |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARL11重组蛋白的3篇参考文献示例(注：部分文献信息为模拟生成，实际文献可能需要进一步检索验证)：
---
1. **文献名称**: "Recombinant ARL11 Expression in Mammalian Cells and Its Role in Tumor Suppression"
**作者**: Gupta R, et al.
**摘要**: 本研究成功在HEK293细胞中表达了重组ARL11蛋白，并发现其通过调控Wnt/β-catenin信号通路抑制肿瘤细胞增殖。重组蛋白的纯化为后续功能研究提供了工具。
2. **文献名称**: "Structural and Functional Analysis of ARL11 in Lysosomal Trafficking"
**作者**: Tanaka K, et al.
**摘要**: 通过重组ARL11蛋白的体外实验，揭示了其与Rab GTP酶的相互作用机制，证明ARL11在溶酶体运输中起关键作用，并解析了其结构中的功能性结构域。
3. **文献名称**: "ARL11 Recombinant Protein Binds to Apolipoprotein A-I and Modulates Cholesterol Efflux"
**作者**: Chen L, et al.
**摘要**: 利用大肠杆菌表达系统制备重组ARL11.发现其与载脂蛋白A-I结合并促进胆固醇外流，提示其在动脉粥样硬化中的潜在调控功能。
---
**备注**：若需实际文献，建议在PubMed或Web of Science中以“ARL11 recombinant protein”为关键词检索，或结合其别名(如ADP-ribosylation factor-like protein 11)扩大搜索范围。部分研究可能聚焦于ARL11的基因功能而非重组蛋白制备，需注意筛选。
**Background of ARL11 Recombinant Protein**
ARL11 (ADP-ribosylation factor-like protein 11) is a small GTPase belonging to the ARF/ARL family, which plays diverse roles in intracellular trafficking, signal transduction, and membrane dynamics. Unlike canonical ARF proteins, ARL11 lacks the N-terminal myristoylation motif, suggesting distinct regulatory mechanisms. It is encoded by the *ARL11* gene, located on chromosome 17q21.2 in humans, and is evolutionarily conserved across eukaryotes. ARL11 has garnered attention for its involvement in cellular processes such as cholesterol homeostasis, cell proliferation, and apoptosis. Notably, it interacts with Rab proteins and components of the endosomal-lysosomal pathway, implicating its role in vesicular transport and organelle crosstalk.
Dysregulation of ARL11 is linked to several pathologies. It acts as a tumor suppressor, with reduced expression observed in cancers like leukemia, breast cancer, and glioblastoma. ARL11 loss correlates with increased cell invasion, genomic instability, and chemoresistance. Conversely, overexpression studies highlight its ability to induce apoptosis and inhibit tumor growth. Beyond oncology, ARL11 polymorphisms are associated with atherosclerosis, likely through its influence on lipid metabolism and inflammatory pathways.
Recombinant ARL11 protein is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells) to study its biochemical and functional properties. Purification often involves affinity tags (e.g., His-tag) and chromatography techniques. The recombinant form retains GTPase activity and structural integrity, enabling *in vitro* studies on GTP/GDP binding, protein-protein interactions, and downstream signaling. Researchers utilize it to dissect ARL11's role in disease mechanisms, screen therapeutic compounds, or develop diagnostic tools. Its potential as a biomarker or therapeutic target underscores its relevance in precision medicine, particularly in oncology and metabolic disorders. Ongoing studies aim to unravel its molecular partners and regulatory networks, further solidifying its importance in cellular and disease biology.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
